secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001728117-21-000103
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Q3 net loss $60.2M ($0.80/shr); PAH study topline delayed to H2 2022
-----------------------------------------------------------------------------

- Net loss $60.2M for Q3 2021 vs $57.8M prior year, R&D $43.2M, G&A $12.5M.
- Cash, equivalents and securities $366M as of Sept 30, 2021; sufficient into H2 2023.
- Phase 2 TORREY (PAH) topline results now expected H2 2022 due to COVID-19 delays.
- Phase 2 SHIFT-UC (ulcerative colitis) completed enrollment; topline Q2, treat-through data Q4 2022.
- GB5121 advanced to Phase 1 healthy volunteers; GB7208 (MS) Phase 1 expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811721000103/0001728117-21-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811721000103/goss-20211108.htm
  HTML page:      https://secwatch.observer/filing/0001728117-21-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer